GNF-7

Target: This ligand targets BCR-ABL/ABL1, including resistant ABL1 mutant kinase forms in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for BCR-ABL/ABL1, including resistant ABL1 mutant kinase forms. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings BCR-ABL/ABL1 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Degradation: GNF-7 can be used as a ligand component in PROTAC constructs to recruit an E3 ligase and induce targeted degradation of its associated protein target. This enables systematic evaluation of degrader potency, degradation kinetics, and dose–response relationships in cellular models, supporting mechanism-of-action studies and pathway mapping.

• Target Engagement Optimization: Incorporating GNF-7 into PROTAC designs allows researchers to tune linker length and attachment chemistry to maximize productive ternary complex formation. By monitoring target loss alongside signaling readouts, investigators can refine binding orientation and residence time, improving the likelihood of efficient ubiquitination and proteasome-dependent degradation.

• Pathway Mechanism Studies: PROTACs built with GNF-7 facilitate functional dissection of target-dependent signaling networks by comparing degradation versus inhibition phenotypes. Quantifying downstream transcriptional and proteomic changes helps determine whether observed biological effects arise from complete protein depletion, partial degradation, or compensatory responses.

• Comparative Degrader Profiling: Using GNF-7-based PROTACs enables head-to-head comparisons across E3 ligase recruiters, linker architectures, and dosing schedules. Such profiling supports identification of degrader formats that yield deeper target knockdown, reduced rebound effects, and improved selectivity, guiding rational selection of lead candidates for further mechanistic and translational research.

GNF-7 is a ABL/Src-family kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of GNF-7 is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.